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The hepatocellular carcinoma (HCC) is one of the most common malignant tumors and carries a poor survival rate. The
management of patients at risk for developing HCC remains challenging. Increased understanding of cancer biology and
technological advances have enabled identiﬁcation of a multitude of pathological, genetic, and molecular events that drive
hepatocarcinogenesis leading to discovery of numerous potential biomarkers in this disease. They are currently being aggressively
evaluated to establish their value in early diagnosis, optimization of therapy, reducing the emergence of new tumors, and
preventingtherecurrenceaftersurgicalresectionorlivertransplantation.Thesemarkersnotonlyhelpinpredictionofprognosisor
recurrencebutmayalsoassistindecidingappropriatemodalityoftherapyandmayrepresentnovelpotentialtargetsfortherapeutic
interventions. In this paper, a summary of most relevant available data from published papers reporting various tissue and serum
biomarkers involved in hepatocellular carcinoma was presented.
1.Introduction
As molecular indicators of biological status, biomarkers,
detectableinblood,urine,ortissue,canbeusefulfortheclin-
icalmanagementofvariousdiseasestates.Thresholdconcen-
trations can be utilized to identify the presence of various
diseases. Concentration ﬂuctuations have the potential to
guide therapy in disease progression. Numerous biomarkers
have been identiﬁed for various disease states. Research is
ongoing to fully understand and evaluate the clinical signiﬁ-
cance of utilizing biomarkers. Time and money can be
saved by avoiding empiric or broad treatment approaches
to diseases of particular organs or systems, and ideally, bio-
markers could serve as a measurement tool to detect dis-
ease presence and progression and to guide more targeted
therapy. Many disease states, especially various types of can-
cer, can be better understood by the utilization of tumor bio-
markers. Hepatocellular carcinoma (HCC) is one such can-
certhatcanbeneﬁtfromtumorbiomarkers’diagnostic,ther-
apeutic, and prognostic capabilities.
HCC is the ﬁfth most common malignant tumor and
the third leading cause of cancer-related deaths. Worldwide,
there are about 626,000 new HCC cases and nearly 600,000
HCC-related deaths each year with an incidence equal to the
death rate [1, 2]. Although the molecular mechanisms by
which HCC develops remain largely unclear, a multitude of
pathological, genetic, and molecular events that drive hepa-
tocellular carcinogenesis has been identiﬁed.
Current gold standard and most commonly used bio-
markers for patients at risk for HCC, alpha-fetoprotein
(AFP) along with ultrasound every 6 to 12 months, is far
from perfect. Serum AFP levels of more than 400ng/mL
are considered diagnostic; however, such high values are
observed only in a small percentage of patients with HCC.
Ultrasound surveillance even performed at every three
monthly intervals cannot improve detection of small HCC
because of limitations in recall procedures [3, 4].
With advances in understanding of tumor biology, along
with the development of cellular and molecular techniques,
theroleofbiomarkersrelatedtoearlydetection,invasiveness,2 International Journal of Hepatology
metastasis,andrecurrencehasattractedgreatdealofresearch
interest resulting in discovery and utilization of several
novel markers in this disease. In this paper we try to give
an overview of available data on this burgeoning area of
research.
2. Biomarkers for Liver Cancer
2.1. Oncofetal and Glycoprotein Antigens
2.1.1. Alpha-Fetoprotein (AFP). The ﬁrst serologic assay for
detection and clinical followup of patients with hepatocellu-
lar carcinoma was alpha-fetoprotein (AFP) which has been
the standard tumor biomarker for HCC for many years. It is
agl y c o p r o t e i np r o d u c e db yt h ef e t a ll i v e ra n dy o l ks a cd u ri n g
pregnancy. Serum AFP levels are often elevated in HCC,
but this is not always the case. AFP levels may be elevated
initially in the early stages of HCC and then drop or even
normalize before rising again as disease progression occurs
[5]. Additionally, AFP elevation has also been recognized
in the presence of acute and chronic viral hepatitis as well
as in patients with cirrhosis caused by hepatitis C. Given
the multiple indications that present with elevated AFP
levels, it is necessary to evaluate the signiﬁcance of serum
concentrations. In general, consistently elevated serum AFP
levels greater than 500ng/mL are indicative of HCC. Lower
serum concentrations which are only transient in nature are
more often present in benign liver disease [6]. If a patient has
knownriskfactorsforHCC,suchasthepresenceofcirrhosis,
increasing levels of AFP have been shown to correlate with
the development of HCC [6]. Unfortunately, AFP serum
concentrations do not correlate well with the prognostic val-
ues of HCC such as tumor size, stage, or disease progression,
and ethnic variability may also exist. Furthermore, in some
casesofHCC,AFPelevationsarenotapparentatall[7].Total
AFP can be divided into three diﬀerent glycoforms, AFP-L1,
AFP-L2, and AFP-L3-based on their binding capability to
lectin Lens culinaris agglutinin (LCA). High percentage
of AFP-L3 has been shown to be associated with poor dif-
ferentiationandbiologicallymalignantcharacteristics,worse
liver function, and larger tumor mass [8].
2.1.2. Glypican-3. Glypican-3 (GPC3), a membrane-an-
chored heparin sulfate proteoglycan, has been demonstrated
to interact with growth factors and modulate their activities.
It binds to the cell membrane through the glycosylphos-
phatidylinositol anchors. GPC3 mRNA was upregulated sig-
niﬁcantlyintumortissuesofHCCcomparedtoparaneoplas-
tic liver tissue, liver tissues of healthy adults, and liver tissues
of patients with nonmalignant hepatopathy. The expression
of GPC3 (at both mRNA and protein levels) in the serum of
HCC patients was signiﬁcantly higher than that in the serum
of healthy adults or patients with nonmalignant disease. It
can be detected in 40–53% of HCC patients and 33% of
HCC patients seronegative for both AFP and Des-gamma-
carboxyprothrombin (DCP) [9, 10]. It has been shown
that soluble GPC3 (sGPC3), the NH2-terminal portion of
GPC3, is superior to AFP in the sensitivity of detecting well
Table 1: Diagnostic values of HCC serum markers [12–14].
Type of test Sensitivity
(%)
Speciﬁcity
(%)
AFP-L3 61.6 92.0
DCP 72.7 90.0
AFP 67.7 71.0
AFP-L3 + DCP 84.8 97.8
AFP-L3 + AFP 73.7 86.6
DCP + AFP 84.8 90.2
AFP-L3 + DCP + AFP 85.9 59.0
or moderately diﬀerentiated HCC, and the simultaneous
determination of both markers improves overall sensitivity
from 50% to 72%. Recently, a study compared the survival
rate between the GPC3-positive and GPC3-negative HCC
patients. GPC3 positivity correlatedwithpoor prognosis and
identiﬁed as an independent prognostic factor for the overall
survival on multivariate analysis [11].
2.2. Enzymes and Isoenzymes
2.2.1. Des-Gamma-Carboxy (Abnormal) Prothrombin (DCP).
DCP is produced by the malignant hepatocyte and appears
to result from an acquired posttranslational defect in the
vitamin-K-dependent carboxylase system. DCP production
is independent of vitamin K deﬁciency, although phar-
macological doses of vitamin K can transiently suppress
DCP production in some tumors. DCP levels greater than
0.1AU/mL (100ng/mL) on ELISA are highly suggestive of
HCC or tumor recurrence. Normalization of DCP levels
correlates well with successful tumor resection and appears
to be an excellent marker of tumor activity. It is thought that
the combination of AFP and DCP assays will increase the
sensitivity of testing. The correlation between tumor size and
DCP levels is not yet clearly deﬁned. It appears that there
is a correlation in DCP levels and large tumors; however,
the same is not the case in small tumors (<3cm) [15].
A cross-sectional case control study involving 207 patients
determined that DCP is more sensitive and speciﬁc than AFP
for diﬀerentiating HCC from nonmalignant liver disease. In
this study there were 4 groups studied: normal healthy sub-
jects; patients with noncirrhotic chronic hepatitis, patients
with compensated cirrhosis, and patients with histologically
proven HCC. Both DCP and AFP levels increased among the
groups as disease severity increased (from normal to HCC),
but DCP values had less overlap among the groups than AFP.
Study results concluded that a DCP value of 125mAU/mL
yielded the best sensitivity and speciﬁcity for diﬀerentiating
patients with HCC from those with cirrhosis and chronic
hepatitis [16]. Sensitivity and speciﬁty of total AFP, AFP
glycoforms, DCP, and combinations of both markers have
been summarized in Table 1.
2.2.2. Gamma-Glutamyl Transferase. Serum gamma-gluta-
myl transferase (GGT) in healthy adults is mainly secreted
by hepatic Kupﬀer cell and endothelial cell of bile duct,International Journal of Hepatology 3
and its activity increases in HCC tissues. Total GGT can be
divided into 13 isoenzymes by using polymer acrylamide
gradient gel electrophoresis, and some of them can only
be detected in the serum of HCC patients. Sensitivities of
GGTII have been reported to be 74.0% in detecting large
HCC and 43.8% in detecting small HCC. Sensitivity can be
signiﬁcantly improved with the simultaneous determination
of GGTII, DCP, and AFP [17].
2.2.3. Serum Alpha-1-Fucosidase. Alpha-l-fucosidase (AFU)
is a lysosomal enzyme found in all mammalian cells with
a function to hydrolyze fucose glycosidic linkages of gly-
coprotein and glycolipids. Its activity increases in the se-
rum of HCC patients (1418.62 ± 575.76nmol/mL/h) com-
pared with that in the serum of healthy adults (504.18 ±
121.88nmol/mL/h, P<0.05), patients with cirrhosis
(831.25 ± 261.13nmol/mL/h), and patients with chronic
hepatitis (717.71 ± 205.86nmol/mL/h). It has been reported
that the sensitivity and speciﬁcity of AFU at the cut-oﬀ
value of 870nmol/mL/h were 81.7% and 70.7%, respectively
[18]. AFU measurement is useful in association with AFP
in early diagnosis of HCC and could serve as a valuable
supplementary to AFP. It has been indicated that HCC will
develop within few years in 82% of patients with liver cir-
rhosis, if their serum AFU activity exceeds 700nmol/mL/h.
T h ea c t i v i t yo fA F Uw a sr e p o r t e dt ob ee l e v a t e di n8 5 %o f
patients at least 6 months before the detection of HCC by
ultrasonography [19].
2.2.4. Human Carbonyl Reductase 2. This enzyme expressed
in the human liver and kidney is important in detoxiﬁcation
of the reactive alpha-dicarbonyl compounds and reactive
oxygen species deriving from oxidative stress in HCC. The
human carbonyl reductase 2 levels have been shown to be
inversely correlated to the pathological grading of HCC [20].
2.2.5. Golgi Phosphoprotein 2. Golgi phosphoprotein 2
(GOLPH2), a Golgi-apparatus-associated protein, has been
shown to have a higher sensitivity than AFP in the detection
of HCC [21]. A recent study found that GOLPH2 protein
was highly expressed in tissues of HCC (71%) and bile
duct carcinoma (85%) patients. GOLPH2 protein levels were
detectable and quantiﬁable in sera by ELISA. In patients
with hepatitis C, serial ELISA measurements in the course of
the disease appear to be a promising complimentary serum
marker in the surveillance of HCC [22].
2.3. Growth Factors and Their Receptors
2.3.1.TransformingGrowthFactor-Beta(TGF-Beta). Belong-
ing to a superfamily of polypeptide signaling molecules in-
volved in regulating cell growth, diﬀerentiation, angiogen-
esis,invasion, andimmunefunction,TGF-betaisapredomi-
nant form of growth factor family in humans. Its mRNA
and protein are overexpressed in HCC compared with sur-
rounding liver tissues, especially in small and well-diﬀeren-
tiated HCCs [23]. However, no relationship has been shown
between TGF-beta expression and posthepatectomy survival
[24]. Serum TGF-beta level has been found to be elevated in
HCC patients compared to healthy adults or patients with
nonmalignant liver disease [25–27].
2.3.2. Tumor-Speciﬁc Growth Factor (TSGF). Malignant tu-
mors release tumor-speciﬁc growth factor (TSGF) into
peripheral blood during their growing period. Serum levels
ofTSGFmayreﬂecttheexistenceoftumor.TSGFcanbeused
as a diagnostic marker in detecting HCC, and its sensitivity
can reach 82% at the cut-oﬀ v a l u eo f6 2U / m La n dm a yh a v e
a higher accuracy with the simultaneous determination of
other tumor markers. The simultaneous determination of
TSGF (at the cut-oﬀ value of 65U/mL), AFP (at the cut-oﬀ
value of 25ng/mL), and serum ferritin (at the cut-oﬀ value
of 240ng/mL) can reach a sensitivity and speciﬁcity of 98.4%
and 99%, respectively [26].
2.3.3. Epidermal Growth Factor Receptor Family. The epider-
mal growth factor receptor (EGFR) family consists of four
closely related transmembrane tyrosine kinase receptors:
EGFR (erbB-1), c-erb-2 (Her-2/neu), c-erb-3 (HER-3), and
c-erb-4 (HER-4). These bind with ligands of the EGF
family,includingEGF,TGF-alpha,andheparin-bindingEGF.
High levels of EGFR expression have been associated with
early recurrence and reduced disease-free survival following
resection of hepatocellular carcinoma [27].
2.3.4. Hepatocyte Growth Factor/Scatter Factor. Hepatocyte
growth factor/scatter factor (HGF/SF) is a cytokine with a
wide range of eﬀects from embryonic development and liver
regeneration. It is associated with molecular mechanisms
of hepatocarcinogenesis via paracrine system involving its
cellular receptor, c-met. High c-met expression has been
shown in invasive-type HCC and has been associated with
metastasis and reduced overall survival [28, 29].
2.3.5. Basic Fibroblast Growth Factor. This is a soluble hepa-
rin-binding polypeptide with a potent mitogenic eﬀect on
endothelial cells. Elevated levels above the median of
>10.8pg/mL have been shown to predict decreased disease-
free survival [30]. Recent preliminary data with targeted
therapy lenalidomide which inhibits ﬁbroblast growth factor
(FGF) showed promising and in some patients dramatic
activity in HCC patients [31].
2.4. Molecular Markers
2.4.1. Circulating Nucleic Acids: mRNAs. The analysis of cir-
culating nucleic acids in plasma oﬀers another avenue for
noninvasive monitoring of a variety of physiological and
pathologicconditions[30,31].Numerousapplicationsbased
on the detection of circulating cell-free nucleic acids in
human plasma have been reported for the management of
malignancies. The fundamental principle underlying these
applications relates to the detection in plasma of extracel-
lular nucleic acid molecules derived from diseased organs.
Analysis of cell-free plasma RNA oﬀers an opportunity for
the development of pathology-related markers [32–34].4 International Journal of Hepatology
Alpha-Fetoprotein mRNA (AFP mRNA). Matsumura et al.
ﬁrst reported that single HCC cell could be detected in cir-
culation by means of reverse-transcription polymerase chain
reaction (RT-PCR), targeting AFP mRNA [35]. This led to
further reports of the value of AFP mRNA as a predictor for
HCC recurrence. Rather controversial results were attributed
tothebloodbornedispersionofbothtumorcellsandnormal
liver cells and the mistranscription of mRNA encoding
AFP by peripheral mononuclear cells. The recurrence-free
interval of HCC patients with postoperative serum AFP
mRNApositivityhasbeenreportedtobesigniﬁcantlyshorter
than that of HCC patients with postoperative negativity
(53% versus 88% at 1 year, 37% versus 60% at 2 years,
P = 0.014) [34] and (52.6% versus 81.8% at 1 year, 15.6%
versus 54.5% at 2 years, and 0% versus 29.2% at 3 years,
P<0.001) [36]. A meta-analysis showed that the expression
ofAFPmRNAoneweekaftersurgerywascorrelatedwiththe
recurrence of HCC [37].
Gamma-GlutamylTransferasemRNA(GGTmRNA). Similar
to AFP, GGT mRNA can be detected in the serum and liver
tissues of healthy adults, patients with liver disease, benign
liver tumor, HCC, and secondary tumors of the liver [38].
T h et w ot y p e so fG G Tm R N A ,t y p eAa n dt y p eB ,h a v eb e e n
identiﬁed. Type B is the predominant one in cancerous tissue
suggesting that changes in the expression of hepatic GGT
mRNA may be related to the development of HCC [39].
Patients with HCC harboring type B GGT mRNA both in
cancer and in noncancerous tissue had a worse outcome,
earlier recurrence, and more recurrence-related mortality.
The presence of type B GGT mRNA in cancerous tissue was
statisticallycorrelatedwithhighserumlevelofAFP,daughter
nodules, higher postresection recurrence rate than those
without it (63.6% versus 14.3%), and lower postrecurrence
survival. The presence of type B GGT mRNA in non-
cancerous liver tissue was signiﬁcantly correlated with hep-
atitis C infection, high serum level of AFP, absence of inﬁl-
tration of capsule, vascular permeation, daughter nodules,
postresection recurrence, and postrecurrence survival [40].
Insulin-Like Growth Factor II (IGF-II) mRNA. Abnormal
expression of IGF-II mRNA can be a useful tumor marker
for diagnosis, diﬀerentiation, extrahepatic metastasis, and
monitoring of postoperative recurrence in HCC. The deter-
mination of serum insulin-like growth factor-II (IGF-II) (at
the cut-oﬀ value of 4.1mg/g, prealbumin) has a sensitivity
of 63%, speciﬁcity of 90%, and accuracy of 70% in the
diagnosis of small HCC [41]. It can be a complementary
tumor marker to AFP for diagnosis of small HCC. The
simultaneous determination of IGF-II and AFP (at the cut-
oﬀvalueof50ng/mL)canimprovethesensitivityto80%and
accuracy to 88% [42].
Albumin mRNA. Albumin is the most abundant protein
in the body synthesized by the liver. mRNA of albumin is
detectable in human plasma and could be a diagnostically
sensitive marker for liver pathologies. Extracellular-based
assays (circulating DNA/RNA) have been found to be better
than cell-based assays (circulating tumor cells) in detection
ofpreneoplasticlesionsandmicrometastasesasplasmalevels
of circulating cancer-derived nucleic acid are higher than
the levels of circulating cancer cells and are less prone
to sampling errors. Cheung and colleagues studied the
preoperativeplasmasamplesobtainedfrom72HCCpatients
who had undergone liver transplantation and found that
patients with plasma albumin mRNA level (>14.6) had a
signiﬁcantly higher recurrence rate on multivariate analysis.
High plasma albumin mRNA level predicted the 2-year
recurrence rate with sensitivity and speciﬁcity of 73% and
70%, respectively [43].
MicroRNAs (miRNAs). MicroRNAs (miRNAs) are a family
of endogenous, small (21–23 nucleotides), noncoding but
functional RNAs, which have been found in worms, ﬂies,
and mammals including human beings [44]. It is estimated
that there are about 1,000 miRNA genes in the human
genome with approximately 500 miRNA genes being already
identiﬁed [45]. Similar to mRNA, HCC-associated miRNAs
could be used as diagnostic and prognostic biomarkers of
HCC with a potential for even greater accuracy. MiRNAs
can accurately predict whether liver cancer will spread and
whether liver cancer patients will have shorter or longer
survival. MicroRNAs regulate gene expression by binding to
speciﬁc messenger RNAs and prevent their translation into
protein. Because each type of miRNA is able to downregulate
hundreds of genes at a time, they can control entire tran-
scriptional programs that determine fundamental cellular
properties and behavior. Accordingly, miRNA proﬁling has
emerged as an extremely valuable method for phenotyping
and subclassifying tumors [44]. Compared to conventional
gene expression proﬁling (in which protein-coding, mes-
senger RNAs are examined), miRNA analysis has several
advantages. Due to the stability of miRNAs, formalin-ﬁxed
samples (rather than frozen tissue) can be used. Further-
more, the interrogation of hundreds of miRNAs (and often
signiﬁcantly fewer) yields as much information as might be
gleaned from examining thousands of messenger RNAs.
Many independent groups have conducted compre-
hensive analyses of miRNAs in HCC, and a plethora of
informationonmiRNAmarkershasbeenidentiﬁed.Manyof
these miRNA signatures correlate with important biological
parameters, such as metastasis [46–48], diﬀerentiation [49–
51], HBV or HCV infection [52, 53], tumor recurrence
[54], and patient survival [55, 56]. Some miRNAs are
involved in HCC carcinogenesis by promoting cancer stem
cell and by controlling cell proliferation and apoptosis;
others are associated with HCC progression by controlling
cell migration and invasion. These HCC-associated miRNAs
not only provide new insights into the molecular basis
of HCC but also serve as new tools for HCC diagnosis
and prognosis. Currently a few miRNA signatures, however,
could potentially be used in this area. Some miRNAs have
been validated in an independent cohort, paving the way for
clinically useful platforms to assess HCC risk and outcome.
This promising area of research awaits further validation in
p r o s p e c t i v es t u d i e s[ 57].International Journal of Hepatology 5
Table 2: Various HCC biomarkers and their clinical use.
HCC marker Clinical use
Alpha-fetoprotein Early diagnosis, monitoring, and recurrence
Lens culinaris agglutinin reactive AFP (AFP-L3%) Early diagnosis and prognosis, vascular invasion
Des-gamma-carboxy prothrombin (DCP) Early diagnosis and prognosis, portal vein invasion and metastasis
Gamma-glutamyl transferase Early diagnosis complementary to other markers
Alpha-l-fucosidase Early diagnosis
Glypican-3 Early diagnosis
Human carbonyl reductase 2 Prognosis
Golgi phosphoprotein 2 Tumor aggressiveness
Transforming growth factor beta Tumor invasiveness
Hepatocyte growth factor (HGF) Prognosis and disease recurrence
Transforming growth factor-b (TGF-b) Prognosis invasiveness
Tumor speciﬁc growth factor Diagnosis complementary to other markers
Epidermal growth factor receptor family Early recurrence
Hepatocyte growth factor Metastasis reduced survival
Micro RNAs Tumor spread and survival
2.5. Pathological Biomarkers. Finally there have been reports
of pathological biomarkers of HCC for diagnosis and pro-
gnosis. Some of these diagnostic biomarkers focus on immu-
nochemical staining patterns to distinguish high-grade dys-
plastic nodules and well-diﬀerentiated HCC. The best type
of immunostaining for this diﬃcult condition has been
reported to be the combination of heat-shock protein 70
(HSP70), glypican-3 (GPC3), and glutamine synthetase
(GS).Forprognosticuseanumberofhistologicalandimmu-
no-histochemical markers such as markers of cell prolifera-
tion (Ki67), apoptosis or cell survival (survivin), cell adhe-
sion molecules (E-cadherin), neoangiogeneis (VEGF), and
more have been looked in small studies showing promise;
however, most of these markers have not been validated in
largestudies[57].VariousHCCbiomarkersandtheirclinical
u s eh a v eb e e ns u m m a r i z e di nTable 2.
3. Discussion
Hepatocarcinogenesisisacomplexmultistateprocessusually
occurring after many years of chronic exposure to sev-
eral mitogenic and mutagenic environments precipitating
random genetic alterations. Recent evidence suggest that
intrinsic biologic characteristics of the tumor in terms
of proliferation and invasiveness are probably related to
diﬀerent composition and activity of the microenvironment,
leading to very diﬀerent clinical outcomes. HCC is rather
unique with its ability to synthesize various tumor-related
proteins rendering itself more suitable to biomarker-related
researchthanothertumors.Becauseofthelargemultitudeof
biomarkers reported in this disease, selecting the biomarkers
which would be most useful in clinical practice has been
more than challenging. In this rather brief overview, we tried
to focus on most widely used and accepted biomarkers.
Despite its limitations, serum AFP still remains the
most widely used tumor marker in clinical practice. Recent
research favors the circulating hepatoma-speciﬁc AFP sub-
fraction AFP-L3 and DCP over AFP alone in diﬀerentiating
HCC from nonmalignant hepatopathy and detecting small
HCC. Furthermore, some other tumor markers, such as
GPC3, GGT II, AFU, have been shown to be supplementary
to AFP and DCP in the detection of HCC. Some of them
even can be detected in HCC patients seronegative for
both AFP and DCP, thus indicating that the simultaneous
determination of these markers may improve the accuracy.
However, most exciting and promising area of research
in this disease has been the identiﬁcation of a new group of
molecules called miRNAs. MiRNAs have been discovered to
be aberrantly expressed in HCC, and some of them are func-
tionally involved in HCC carcinogenesis and progression.
Furthermore, certain microRNAs are associated with HCC
or related to HCC subtypes, implicating the potential use of
microRNAs in HCC patient stratiﬁcation of diagnosis and
prognosis.SomeoftheseHCC-associatedmiRNAshavebeen
validated in independent cohorts. This brings the possibility
of developing clinically useful platforms to develop HCC
diagnosis,riskassessment,andpatientriskstratiﬁcationwith
the ultimate goal of personalized therapy.
4. Conclusion
Research into the molecular biology of hepatocarcinogenesis
has identiﬁed numerous biomarkers which could provide
additionalinformationforHCCbiologicbehaviormetastasis
and recurrence to that gained from traditional histopatho-
logical features. A large number of biomarkers have been
shown to have potential predictive signiﬁcance. However,
most of them have been studied retrospectively. Eﬀorts
should be directed towards prospective clinical trials in eval-
uating the prognostic signiﬁcance of these markers. These
molecules not only help in prediction of prognosis for pa-
tients with HCC but may also assist in deciding appropriate6 International Journal of Hepatology
modalityoftherapyandrepresentnoveltargetsfortherapeu-
tic interventions.
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